B-cell lymphoma

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

Retrieved on: 
Thursday, January 20, 2022 - 12:15pm

A live webcast will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com.

Key Points: 
  • A live webcast will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

Retrieved on: 
Wednesday, January 19, 2022 - 1:00pm

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference on Friday, January 28, 2022.

Key Points: 
  • BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference on Friday, January 28, 2022.
  • A live webcast of the fireside chat from the B. Riley Securities Oncology Investor Conference will be available on the investors section of the X4 Pharmaceuticals website at www.x4pharma.com .
  • After the live webcast, the event will remain archived on the X4 Pharmaceuticals website for at least 30 days.
  • X4 Pharmaceuticalsis a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with immune system dysfunction.

Foresight Diagnostics Establishes Scientific Advisory Board with Appointment of Sandra Horning, M.D.

Retrieved on: 
Wednesday, January 19, 2022 - 2:00pm

AURORA, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced the appointment of Sandra Horning, M.D., FACP, FASCO, to its newly established Scientific Advisory Board (SAB).

Key Points: 
  • AURORA, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced the appointment of Sandra Horning, M.D., FACP, FASCO, to its newly established Scientific Advisory Board (SAB).
  • Sandra has been at the forefront of biopharmaceutical innovation for many years, and brings significant experience and insight to our team, said Jake Chabon, Ph.D., co-founder and Chief Executive Officer of Foresight Diagnostics.
  • We look forward to Sandras contributions to Foresight as we realize our vision for improved patient care.
  • Dr. Horning is a co-founder and board member of EQRx and currently serves on the Boards of Directors at Gilead Sciences, Moderna and Olema Oncology.

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

Retrieved on: 
Tuesday, January 18, 2022 - 10:00am

ADC Therapeutics will also receive royalties ranging in percentage from the high teens to the low twenties based on net sales of the product in Japan.

Key Points: 
  • ADC Therapeutics will also receive royalties ranging in percentage from the high teens to the low twenties based on net sales of the product in Japan.
  • "MTPC is delighted to collaborate with ADC Therapeutics, a leader in the field of antibody drug conjugates, to develop and commercialize ZYNLONTA in Japan, said Hiroaki Ueno, PhD, Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation.
  • We will try to improve the quality of life of patients suffering from cancer with the use of ADC Therapeutics novel anti-CD19 ADC, ZYNLONTA.
  • In addition, Overland ADCT BioPharma, a joint venture formed by Overland Pharmaceuticals and ADC Therapeutics, is working to develop and commercialize ZYNLONTA in greater China and Singapore.

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851

Retrieved on: 
Wednesday, January 12, 2022 - 12:30pm

Dosing the first patient in the phase 1 combination trial with CYT-0851 is an important milestone in the development of CYT-0851.

Key Points: 
  • Dosing the first patient in the phase 1 combination trial with CYT-0851 is an important milestone in the development of CYT-0851.
  • The Phase 1 combination trial with CYT-0851 is with three standard-of-care regimens: rituximab plus bendamustine, gemcitabine, and capecitabine, in both hematologic malignancies and solid tumors (NCT Number NCT03997968).
  • Once the Phase 1 dose-finding portion for combinations is complete, CYT-0851 may move into Phase 2 dose confirmation and signal seeking combination cohorts.
  • Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer.

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

Retrieved on: 
Tuesday, January 11, 2022 - 11:00am

SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with the National Cancer Institution (NCI), an institute of the National Institutes of Health (NIH), for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor (CAR) with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.

Key Points: 
  • Engineered CAR T cell therapies for B cell malignancies use binders to target proteins expressed on the surface of B cells.
  • Unfortunately, incomplete responses or relapses occur in over 50% of CD19 CAR T-treated patients, often due to CD19 antigen loss.
  • CD22, which is also a B cell surface protein, has emerged as an alternative to address failure to achieve durable complete responses with CD19-directed CAR T therapy.
  • We are thrilled to enter an agreement with the NIH for an exclusive license to this fully-human CD22 CAR, particularly given the clinical data with this specific construct to date.

SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong an

Retrieved on: 
Tuesday, January 11, 2022 - 7:55am

The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".

Key Points: 
  • The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".
  • In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year.
  • That reflects the capital market's recognition of the value, management and growth potential of the Company and is a great encouragement to the Company.
  • The selection of the "6th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities.

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Retrieved on: 
Monday, January 10, 2022 - 9:30pm

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials.

Key Points: 
  • The FDA had placed a clinical hold on all five of Allogenes clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogenes ALPHA2 study.
  • Allogene reported today that the investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogenes manufacturing process and had no clinical significance.
  • We are very pleased that our licensed partner Allogene is now able to resume its clinical trials, bringing us one step closer to delivering these innovative therapies to patients with unmet medical needs, said Dr. Andr Choulika, CEO of Cellectis.
  • TALEN gene editing technologies were not involved in the findings leading to the clinical hold.

Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates

Retrieved on: 
Monday, January 10, 2022 - 12:00pm

For Epizyme, 2021 was defined by key organizational changes that reduced our overall operating expenses while we accelerated TAZVERIK commercial adoption.

Key Points: 
  • For Epizyme, 2021 was defined by key organizational changes that reduced our overall operating expenses while we accelerated TAZVERIK commercial adoption.
  • TAZVERIK commercial net sales in the fourth quarter of 2021 are expected to be between $7.0-7.5 million, representing an increase of approximately 35% when compared to $5.2 million in the third quarter of 2021.
  • Total end user demand in the fourth quarter of 2021 is expected to represent at least a 14% increase over third quarter 2021 levels.
  • Epizyme also shared preclinical data on EZM0414 along with the SET-101 Phase 1/1b clinical trial design at the 2021 ASH conference.

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

Retrieved on: 
Monday, January 10, 2022 - 12:05pm

NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer.

Key Points: 
  • NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer.
  • Ms. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations.
  • "Since joining Karyopharm, she has played a significant role in shaping our commercial strategy and strengthening capabilities, resulting in an increase in product revenue in 2021.
  • Sohanya's continued guidance and leadership will be invaluable and I look forward to more great things from her as our new chief commercial officer."